House subpanel approves a boost for device center
This article was originally published in The Gray Sheet
Executive Summary
A House Appropriations subcommittee approved on June 30 a $7 million increase over the $325.7 million that the Obama administration had requested for CDRH's fiscal year 2011 budget ("1The Gray Sheet" Feb. 8, 2010). The subcommittee version of the bill would provide FDA with a total of $3.77 billion for the fiscal year beginning Oct. 1, including $2.57 billion in federal funds and $1.2 billion from various industry user fees. The funds include a $65 million package aimed at bolstering staff reviews of generic drug applications and drug company ads, as well as "more funds to safeguard clinical trials," Subcommittee Chair Rosa DeLauro, D-Conn., said. The bill now goes to the House Appropriations Committee for refinements and approval. The Senate Appropriations subcommittee with jurisdiction has yet to propose funding levels for FDA
You may also be interested in...
Obama Budget Request Would Fund National Device Registry At FDA
The Obama administration's fiscal year 2011 budget request includes $4 million for a new medical device registry that would link unique device identifiers to electronic health data. The registry would be designed and built by FDA
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.